Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Solid Tumors

Last updated: October 10, 2024
Sponsor: Chuangzhen Chen
Overall Status: Active - Recruiting

Phase

2

Condition

Cancer Treatment

Cancer

Treatment

Intestinal Low Dose Radiotherapy-1Gy

PD-1 Inhibitors

Intestinal Low Dose Radiotherapy-3Gy

Clinical Study ID

NCT06076135
ShantouUMC
  • Ages 18-80
  • All Genders

Study Summary

Preclinical and clinical studies have shown that intestinal low dose radiotherapy (ILDR) can enhance antitumor immunity and response to immune checkpoint blockade (ICB). Therefore, the investigators launch a phase Ⅱ trial to evaluate the clinical value of combining ILDR and programmed cell death-1/ -ligand 1 (PD-1/PD-L1) inhibitors in patients with ICB refractory metastatic solid tumor.

This study is designed as a researcher-initiated, two-stage and prospective clinical trial. The target population is patients with advanced metastatic malignant solid tumors who have progressed after immunotherapy. The primary endpoints include objective response rate (ORR), disease control rate (DCR), progression free survival while receiving ILDR combined therapy (PFS2), and lesion-based abscopal response rate. The secondary endpoints include incidence of adverse events (AEs), cancer-specific survival (CSS), and overall response rate (OS).

In the treatment stage Ⅰ, sixteen subjects will be enrolled in this trial. The primary objective of this stage is to evaluate the safety and efficacy of 1Gy ILDR combined with PD-1/PD-L1 inhibitors in immune-resistant metastatic malignant solid tumors, and biomarker exploration for response prediction.

The inclusion criteria, exclusion criteria and sample size for treatment stage Ⅱ will be modified on the basis of results from Stage Ⅰ. The objective of the stage Ⅱ is to determine effects and safety of various dosage regimen of ILDR combined with PD-1/PD-L1 inhibitors in target patients.

Eligible patients will be subjected to 1-3Gy ILDR. Tumor response will be assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as well as Immune related RECIST (iRECSIST). The extent or severity of adverse reactions will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) (version 5.0). Furthermore, tissue samples, stool samples, and peripheral blood samples will be collected for biomarker exploration.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥18 years, ≤80 years, regardless of gender.

  2. ECOG level 0-2.

  3. Expected life span>3 months.

  4. At least one accessible and measurable lesion should be selected as the targetlesion for observation according to RECIST criteria.

  5. Patients with metastatic solid tumors (of any histology) without standard therapyoptions, who have previously received immunotherapy, immunotherapy combined withchemotherapy, or immunotherapy combined with anti-angiogenesis treatment and haveshown disease progression.

  6. The patient is considered ineligible for surgical treatment.

  7. Patients with brain metastases assessed as clinically stable after treatment throughrepeated CT and/or MRI scans are eligible.

  8. Patients have complete clinical and pathological information.

  9. Any psychological, family, social or geographical conditions may hinder compliancewith the research protocol.

  10. Patients are able to understand the informed consent form, voluntarily participate,and sign the informed consent form.

  11. Other indicators accord with the general inclusion criteria for clinical trials.

Exclusion

Exclusion Criteria:

  1. Patients with contraindications to radiation therapy and immunotherapy.

  2. Previous occurrence of unacceptable immune related toxic side effects (immunemyocarditis, pneumonia, etc.).

  3. Patients who were assessed as hyperprogressive disease (HPD).

  4. Patients who have received pelvic and abdominal radiation therapy within 6 monthsprior to enrollment.

  5. The adverse reactions from prior treatment have not yet recovered to a CTCAE5.0rating of ≤ 1 (excluding toxicity that has been determined to be risk-free, such asfatigue or hair loss).

  6. Accompanied by severe infections.

  7. Serious liver disease (such as cirrhosis), kidney disease, respiratory disease, orchronic system diseases such as uncontrollable diabetes and hypertension; Patientswho cannot tolerate radiation therapy.

  8. Clinical symptoms of brain metastases or meningeal metastasis.

  9. The patients with known allergies or allergies to the test drug ingredients.

  10. Substance/alcohol abuse.

  11. Patients who are pregnant or planning to.

  12. Patients participating in other clinical studies that may affect the efficacy/safetyof this clinical study.

  13. Patients who have undergone major surgical procedures within 30 days.

  14. Patients who have received antibiotics, antifungal drugs, antiviral, antiparasiticdrugs, or probiotics within 4 weeks.

Study Design

Total Participants: 16
Treatment Group(s): 6
Primary Treatment: Intestinal Low Dose Radiotherapy-1Gy
Phase: 2
Study Start date:
December 26, 2023
Estimated Completion Date:
September 30, 2026

Connect with a study center

  • Cancer Hospital, Shantou University Medical College

    Shantou, Guangdong 515031
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.